Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
The DOI matches its Crossref record.
Abstract
BACKGROUND: A high proportion of patients with generalized anxiety disorder (GAD) have comorbid depressive illness. The presence of anxiety in depression has significant prognostic implications. Because of mirtazapine's early anxiolytic effects, the present study was undertaken as a preliminary investigation in patients with a diagnosis of major depression with comorbid GAD. METHOD: Mirtazapine was administered to 10 patients with DSM-IV major depressive disorder and comorbid GAD in an 8-week open-label study. Mirtazapine was increased from an initial daily dose of 15 mg to a maximum daily dose of 45 mg. RESULTS: Patients were found to have significant reductions in Hamilton Rating Scale for Depression scores, Hamilton Rating Scale for Anxiety scores, and Beck Depression Inventory scores, with improvement noted after the first week of therapy and continuing improvement over the 8 weeks of study. CONCLUSION: These positive preliminary findings support the further investigation of mirtazapine's potential value as a treatment for generalized anxiety disorder in addition to its established efficacy as an antidepressant drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Review of the Pharmacological and Clinical Profile of Mirtazapine
Anttila, S. A. K., & Leinonen, E. V. J. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00198.x · Cited by 795
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“In the first study, open-label mirtazapine treatment in adults with MDD and co-occurring GAD was associated with improvement in depressive symptom severity and in anxiety symptoms (HAM-A), which was noted following the first week and continuing through the following 8 weeks of treatment [49].”
BackgroundSex differences in stress responses: focus on ovarian hormones
Ter Horst, G. J., Wichmann, R., Gerrits, M., Westenbroek, C., & Lin, Y. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.036 · Cited by 157
Considerations in the management of the patient with comorbid depression and anxiety
Sekula, L. K., DeSantis, J., & Gianetti, V. (2003) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2003.tb00251.x · Cited by 8
Metadata
- Authors
- Goodnick, P. J., Puig, A., DeVane, C. L., & Freund, B. V.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1999-07-15
- Volume
- 60
- Issue
- 7
- Pages
- 446-448
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2074130396
- Cited by
- 73
- References
- 0
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.4088/jcp.v60n0705
- The paper
- Goodnick, P. J., Puig, A., DeVane, C. L., & Freund, B. V. (1999). Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v60n0705
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.